Effects of Alprazolam and Melatonin Used for Premedication on Oxidative Stress, Glicocalyx Integrity and Neurocognitive Functions

Patients with COVID-19 have shown melatonin deficiency. We evaluated the efficacy and safety of administration oral melatonin in patients with COVID-19-induced pneumonia. Patients were randomly assigned in a 1:1 ratio to receive melatonin plus standard treatment or standard treatment alone. The primary outcomes were mortality rate and requirement of IMV. The clinical status of patients was recorded at baseline and every day over hospitalization based on seven-category ordinal scale from 1 (discharged) to 7 (death). A total of 226 patients (109 in the melatonin group and 117 in the control group) were enrolled (median age; in melatonin group: 54.60 ± 11.51, in control group: 54.69 ± 13.40). The mortality rate was 67% in the melatonin group and 94% in the control group (OR; 7.75, 95% CI, 3.27–18.35, P < 0.001). The rate of IMV requirement was 51.4% in the melatonin group and 70.9% in the control group, for an OR of 2.31 (95% CI, 1.34–4.00, P < 0.001). The median number of days to hospital discharge was 15 days (13–17) in the melatonin group and 21 days (14–24) in the control group (OR; 5.00, 95% CI, 0.15–9.84, P = 0.026). Time to clinical status improvement by ≥ 2 on the ordinal scale in was 12 days (9–13) in the melatonin group and 16 days (10–19) in the control group (OR; 3.92, 95% CI, 1.69–6.14, P = 0.038). Melatonin significantly improved clinical status with a safe profile in patients with severe COVID-19 pneumonia. Supplementary Information The online version contains supplementary material available at 10.1007/s10787-022-01096-7.

show abstract

Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial

Ameri

Asadi

Ziaei

et al. 2022

Inflammopharmacol

View full text Add to dashboard Cite

show abstract

Melatonin stabilizes age-dependent alterations in erythrocyte membrane induced by ‘Artificial Light at Night’ in a chronodisrupted model of rat

Verma

Singh

Srivastava

et al. 2022

General and Comparative Endocrinology

View full text Add to dashboard Cite

Melatonin protects against membrane alterations affected by ‘Artificial Light at Night’ in a circadian-disrupted model of rat

Verma

Garg

Singh

et al. 2020

Biological Rhythm Research

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Effects of Alprazolam and Melatonin Used for Premedication on Oxidative Stress, Glicocalyx Integrity and Neurocognitive Functions

Abstract: In light of positive effects on oxidatif stress parameters, melatonin may be considered as a good and safe premedication agent with its anxiolytic, antioxidant and minimal haemodynamic and respiratory effects.

Cited by 3 publications

References 27 publications

Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial

Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial

Melatonin stabilizes age-dependent alterations in erythrocyte membrane induced by ‘Artificial Light at Night’ in a chronodisrupted model of rat

Melatonin protects against membrane alterations affected by ‘Artificial Light at Night’ in a circadian-disrupted model of rat

Contact Info

Product

Resources

About